2
|
Xu HM, Wu MY, Shi XC, Liu KL, Zhang YC, Zhang YF, Li HM. Preliminary Study on the Protective Effects and Molecular Mechanism of Procyanidins against PFOS-Induced Glucose-Stimulated Insulin Secretion Impairment in INS-1 Cells. Toxics 2023; 11:174. [PMID: 36851050 PMCID: PMC9966006 DOI: 10.3390/toxics11020174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Revised: 02/10/2023] [Accepted: 02/11/2023] [Indexed: 06/18/2023]
Abstract
This study aimed to investigate the effects of perfluorooctanesulfonic acid (PFOS) exposure on glucose-stimulated insulin secretion (GSIS) of rat insulinoma (INS-1) cells and the potential protective effects of procyanidins (PC). The effects of PFOS and/or PC on GSIS of INS-1 cells were investigated after 48 h of exposure (protein level: insulin; gene level: glucose transporter 2 (Glut2), glucokinase (Gck), and insulin). Subsequently, the effects of exposure on the intracellular reactive oxygen species (ROS) activity were measured. Compared to the control group, PFOS exposure (12.5, 25, and 50 μM) for 48 h had no significant effect on the viability of INS-1 cells. PFOS exposure (50 μM) could reduce the level of insulin secretion and reduce the relative mRNA expression levels of Glut2, Gck, and insulin. It is worth noting that PC could partially reverse the damaging effect caused by PFOS. Significantly, there was an increase in ROS after exposure to PFOS and a decline after PC intervention. PFOS could affect the normal physiological function of GSIS in INS-1 cells. PC, a plant natural product, could effectively alleviate the damage caused by PFOS by inhibiting ROS activity.
Collapse
Affiliation(s)
- Hai-Ming Xu
- School of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China
- The Key Laboratory of Environmental Factors and Chronic Disease Control of Ningxia, No. 1160, Shengli Street, Xingqing District, Yinchuan 750004, China
| | - Meng-Yu Wu
- School of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China
- The Key Laboratory of Environmental Factors and Chronic Disease Control of Ningxia, No. 1160, Shengli Street, Xingqing District, Yinchuan 750004, China
| | - Xin-Chen Shi
- School of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China
- The Key Laboratory of Environmental Factors and Chronic Disease Control of Ningxia, No. 1160, Shengli Street, Xingqing District, Yinchuan 750004, China
| | - Ke-Liang Liu
- School of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China
- The Key Laboratory of Environmental Factors and Chronic Disease Control of Ningxia, No. 1160, Shengli Street, Xingqing District, Yinchuan 750004, China
| | - Ying-Chi Zhang
- School of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China
- The Key Laboratory of Environmental Factors and Chronic Disease Control of Ningxia, No. 1160, Shengli Street, Xingqing District, Yinchuan 750004, China
| | - Yin-Feng Zhang
- Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao 266021, China
| | - Hong-Mei Li
- School of Public Health and Management, Ningxia Medical University, Yinchuan 750004, China
- The Key Laboratory of Environmental Factors and Chronic Disease Control of Ningxia, No. 1160, Shengli Street, Xingqing District, Yinchuan 750004, China
- The Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, Yinchuan 750004, China
| |
Collapse
|
9
|
Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, Buist N, Terebetski J, Kelly T, Bugianesi R, Priest BT, Dingley KH, Li X, Mitelman S, Salituro G, Trujillo ME, Pachanski M, Kirkland M, Powles MA, Eiermann GJ, Feng Y, Shang J, Howard AD, Ujjainwalla F, Sinz CJ, Debenham JS, Edmondson SD, Nargund RP, Hagmann WK, Li D. Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes. ACS Med Chem Lett 2016; 7:1107-1111. [PMID: 27994747 DOI: 10.1021/acsmedchemlett.6b00314] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2016] [Accepted: 10/06/2016] [Indexed: 11/28/2022] Open
Abstract
GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through a high throughput screen. The lead compound 4 suffered from poor metabolic stability and poor solubility. Lead optimization strategies to improve potency, efficacy, metabolic stability, and solubility are described. This optimization led to compound 20e, which showed significant reduction of glucose excursion in wild-type but not in GPR142 deficient mice in an oral glucose tolerance test (oGTT) study. These studies provide strong evidence that reduction of glucose excursion through treatment with 20e is GPR142-mediated, and GPR142 agonists could be used as a potential treatment for type 2 diabetes.
Collapse
Affiliation(s)
- Liangqin Guo
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Dann L. Parker
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Yi Zang
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Ramzi F. Sweis
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Weiguo Liu
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Edward C. Sherer
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Nicole Buist
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Jenna Terebetski
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Terri Kelly
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Randal Bugianesi
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Birgit T. Priest
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Karen H. Dingley
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Xiaofang Li
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Stan Mitelman
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Gino Salituro
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Maria E. Trujillo
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Michele Pachanski
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Melissa Kirkland
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Mary Ann Powles
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - George J. Eiermann
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Yue Feng
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Jin Shang
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Andrew D. Howard
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Feroze Ujjainwalla
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Christopher J. Sinz
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - John S. Debenham
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Scott D. Edmondson
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Ravi P. Nargund
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - William K. Hagmann
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| | - Derun Li
- Departments of Medicinal Chemistry, ‡Discovery Pharmaceutical Sciences, §Pharmacokenetics Pharmacodynamics Drug Metabolism, ∥Diabetes Research, and #Cardiometabolic Disease, Merck & Co., Inc., MRL, 126 East Lincoln Avenue, PO Box 2000, Rahway, New Jersey 07065, United States
| |
Collapse
|
10
|
Yao XG, Xu X, Wang GH, Lei M, Quan LL, Cheng YH, Wan P, Zhou JP, Chen J, Hu LH, Shen X. BBT improves glucose homeostasis by ameliorating β-cell dysfunction in type 2 diabetic mice. J Endocrinol 2015; 224:327-41. [PMID: 25572265 DOI: 10.1530/joe-14-0721] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Impaired glucose-stimulated insulin secretion (GSIS) and increasing β-cell death are two typical dysfunctions of pancreatic β-cells in individuals that are destined to develop type 2 diabetes, and improvement of β-cell function through GSIS enhancement and/or inhibition of β-cell death is a promising strategy for anti-diabetic therapy. In this study, we discovered that the small molecule, N-(2-benzoylphenyl)-5-bromo-2-thiophenecarboxamide (BBT), was effective in both potentiating GSIS and protecting β-cells from cytokine- or streptozotocin (STZ)-induced cell death. Results of further studies revealed that cAMP/PKA and long-lasting (L-type) voltage-dependent Ca(2) (+) channel/CaMK2 pathways were involved in the action of BBT against GSIS, and that the cAMP/PKA pathway was essential for the protective action of BBT on β-cells. An assay using the model of type 2 diabetic mice induced by high-fat diet combined with STZ (STZ/HFD) demonstrated that BBT administration efficiently restored β-cell functions as indicated by the increased plasma insulin level and decrease in the β-cell loss induced by STZ/HFD. Moreover, the results indicated that BBT treatment decreased fasting blood glucose and HbA1c and improved oral glucose tolerance further highlighting the potential of BBT in anti-hyperglycemia research.
Collapse
MESH Headings
- Animals
- Cells, Cultured
- Diabetes Mellitus, Experimental/drug therapy
- Diabetes Mellitus, Experimental/metabolism
- Diabetes Mellitus, Experimental/physiopathology
- Diabetes Mellitus, Type 2/drug therapy
- Diabetes Mellitus, Type 2/metabolism
- Diabetes Mellitus, Type 2/physiopathology
- Diet, High-Fat
- Drug Evaluation, Preclinical
- Glucose/metabolism
- HEK293 Cells
- Homeostasis/drug effects
- Humans
- Hypoglycemic Agents/pharmacology
- Hypoglycemic Agents/therapeutic use
- Insulin-Secreting Cells/drug effects
- Insulin-Secreting Cells/physiology
- Male
- Mice
- Mice, Inbred C57BL
- Streptozocin
- Thiophenes/pharmacology
- Thiophenes/therapeutic use
Collapse
Affiliation(s)
- Xin-gang Yao
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Xin Xu
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Gai-hong Wang
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Min Lei
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Ling-ling Quan
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Yan-hua Cheng
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Ping Wan
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Jin-pei Zhou
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Jing Chen
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Li-hong Hu
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| | - Xu Shen
- Key Laboratory of Receptor ResearchShanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, ChinaCollege of Life and Environmental SciencesShanghai Normal University, 100 Guilin Road, Shanghai 200234, ChinaDepartment of PharmacologyChina Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
| |
Collapse
|